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ABSTRACT
Synthetic progesterone and 5a/b-pregnane-3,20-dione derivatives were evaluated as in vitro and in vivo
modulators of multidrug-resistance (MDR) using two P-gp-expressing human cell lines, the non-steroido-
genic K562/R7 erythroleukaemia cells and the steroidogenic NCI-H295R adrenocortical carcinoma cells,
both resistant to doxorubicin. The maximal effect in both cell lines was observed for 7a-O-
benzoyloxy,11a(R)-O-tetrahydropyranyloxy-5b-pregnane-3,20-dione 4. This modulator co-injected with
doxorubicin significantly decreased the tumour size and increased the survival time of immunodeficient
mice xenografted with NCI-H295R or K562/R7 cells.
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Introduction
Reversion of multidrug resistance (MDR) remains an important
goal to improve the efficiency of cancer chemotherapy. A major
contributor to the MDR phenotype is P-glycoprotein (P-gp/ABCB1),
a transmembrane protein belonging to the ABC (ATP-binding cas-
sette) family of ATP-dependent transporters. This protein is often
overexpressed in tumour cells after treatment by cytotoxic drugs
and is also present in normal tissues such as blood-brain barrier,
adrenal glands, kidney or liver, for which it has a physiological
role to eliminate xenobiotics, toxics or drugs1. P-gp transports a
wide variety of structurally unrelated molecules including most of
the anticancer drugs, which undergo a mechanism of inactivation
by drug efflux, at the origin of chemoresistance.
Different classes of molecules have been found able to inhibit
P-gp-mediated drug efflux among which several pharmaceutical
agents such as verapamil, diltiazem, nifedipine, cyclosporin A, val-
spodar2, or specifically designed P-gp modulators such as nerati-
nib3, and numerous other compounds4. Comparative studies have
revealed favourable structural features5 and provided data on the
localisation of interaction sites with substrates or modulators6
including photoaffinity labelling7 and mutagenesis experiments8.
However, various difficulties have been encountered in attempts
to improve in vivo activities and to limit toxic side effects9
including unwanted pharmacokinetic interactions, intrinsic
pharmacological activities as well as intrusion within the physio-
logical role of P-gp in normal tissues, thus explaining why clinical
trials have often led to unsatisfactory results.
Since the initial observation of the P-gp-modulating properties
of progesterone10, numerous studies have been undertaken to
obtain improved modulators derived from steroidal hormones or
drugs11–14. A major reason for this choice is the amount of data
concerning their physiologic, pharmacologic, and metabolic prop-
erties as well as their toxicities, biological targets, and transport
mechanisms. Moreover, steroids are multifunctional molecules
facilitating structural modifications for the optimisation of pharma-
cological activities and for the control of metabolic degradation in
vivo. Recently, our laboratory has proposed a simple methodology
based on the conversion of hydroxylated precursors of
5a/b-pregnane and 5b-cholane series to ether and/or ester deriva-
tives which provided efficient modulators of P-gp mediated MDR
when tested in vitro on the resistant non-steroidogenic K562/R7
human erythroleukemia cell line15 using doxorubicin as cytotoxic
drug (Figure 1).
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In the present study, we report results of new biological inves-
tigations aimed at evaluating whether the nine progesterone and
5a/b-pregnane-3,20-dione MDR modulators 1–9 (Figure 1) previ-
ously selected using the K562/R7 cell line can maintain a high
level of activity in vivo. In this view, three major obstacles could
be expected for these compounds according to their structures: (i)
the risks of metabolic deactivation by the enzymes of steroid
metabolism, (ii) the potential hormonal side effects, (iii) the possi-
bility of unacceptable levels of toxicity in vivo. These problems
were successively addressed by comparative in vitro assays made
on the human H295R adrenocortical carcinoma cell line rich in
steroid metabolising enzymes and the metabolically inert K562/R7
cell line, by in vitro measurements of interactions with the human
progesterone receptor (PR) and human pregnane X receptor
(hPXR) and finally by in vivo assays made on mice xenografted
with K562/R7 and NCI-H295R cell lines.
Materials and methods
Drugs and steroids
Doxorubicin, colchicine, vincristine, vinblastine, vinorelbine, pacli-
taxel, mitoxantrone, and cyclosporin A were purchased from
Sigma. Syntheses of steroid modulators were previously
described15. For in vitro experiments, dilutions in culture medium
were extemporaneously made from 10mM solutions in DMSO (or
in water for cyclosporin A). For in vivo experiments, the steroid
modulator 4 (2.7mg) was sonicated in 100mL of benzyl alcohol
until solubilisation. This solution was diluted at 6% (v/v) in physio-
logical serum before injections.
Cell lines and culture conditions
The NCI-H295R human adrenocortical carcinoma cells (donated by
M. Begeot, INSERM-U864) previously characterised as expressing
pathways of steroid biosynthesis16 were grown at 37 C in a 5%
CO2 atmosphere using a 1:1 mixture of DMEM and Ham’s F-12
medium, supplemented with L-glutamine (2mM), antibiotics
(50 mg/mL streptomycin, 50U/mL penicillin), ITS þ 1 (mixture of
insulin, transferrin, and sodium selenite, from Sigma), 2% Ultroser
G and SF (Life Science Technologies). The K562 human erythroleu-
kemia cell line and the doxorubicin-resistant K562/R7 cell line
(provided by C. Dumontet) were cultured as previously
described15. The human promyelocytic HL60-MRP1 cell line over-
expressing the Multidrug Resistance Protein 1 (MRP1/ABCC1) and
resistant to doxorubicin and the human breast adenocarcinoma
MCF7-MTX cell line expressing the Breast Cancer Resistance
Protein (BCRP/ABCG2) and resistant to mitoxantrone (donated by
A. di Pietro, IBCP-CNRS) were both cultured at 37 C in a 5% CO2
atmosphere using either (HL60-MRP1 cells) an RPMI 1640 medium
supplemented with 10% FCS, 58 nM of doxorubicin and 70 nM of
vincristine or (MCF7-MTX cells) a 1:1 mixture of DMEM and Ham’s
F-12 medium supplemented with 10% FCS, L-glutamine (2mM),
antibiotics (50mg/mL streptomycin and 50U/mL penicillin). Media
and supplements were obtained from PAA (Velizy, France).
Isolation of RNA and real-time RT-PCR
Total RNA extraction from NCI-H295R cells, first-strand cDNAs syn-
thesis and real-time PCR were performed as previously described
for K562/R7 cells15. Results were expressed as relative levels after
normalisation by G3PDH (glyceraldehyde 3-phosphate dehydro-
genase) mRNA.
Cytotoxicity analysis by MTT assay
Viability of K562/R7 cells was determined by the 3–(4,5-
dimethylthiazolyl-2)–2,5-diphenyltetrazolium bromide (MTT)
reagent as described15,17.
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Figure 1. Structures of synthetic steroid modulators.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 685
Cytotoxicity analysis by [3H]thymidine incorporation assay
NCI-H295R cells (150,000/400 mL of medium) were seeded into 24-
well plates and after cell attachment (24 h), culture medium was
replaced by fresh medium (1ml) containing doxorubicin at 10mM
either alone or in presence of steroid modulators or cyclosporin A
at three concentrations (0.1, 1, and 10mM). After incubation for
24 h at 37 C, the medium was replaced by medium containing
1 mCi/mL of [methyl-3H]thymidine] (GE-Healthcare). After another
24 h incubation, the medium was discarded and cells were precipi-
tated by 1ml of aqueous 10% trichloroacetic acid (TCA) solution.
After incubation for 15min at 4 C, the precipitate was washed by
500 mL of 5% TCA, solubilised by addition of sodium deoxycholate
(300 mL of 4% solution in 0.5M NaOH)18 and counted for radio-
activity (Tri-Carb 1900 CA, Packard). K562 and K562/R7 cells
(150,000/400 mL of medium) were distributed in 24-well plates and
incubated with 600 mL of medium containing doxorubicin, steroids
or cyclosporin A as above, and treated by 1 mCi of [3H]thymidine
as described for NCI-H295R cells. After treatment with TCA, cells
were centrifuged (1000 rpm, 5min), washed with phosphate-buf-
fered saline (PBS), and counted for radioactivity. Results were
expressed as the percentage of incorporated [3H]thymidine in
treated cells vs. untreated cells. The assays were performed in trip-
licate and means ± SE were calculated from three independent
measurements. For the determination of IC50 values, NCI-H295R or
K562/R7 cells were incubated for 24 h with increasing concentra-
tions of tested cytotoxic drugs (0.01–100mM), in the absence or
presence of a fixed concentration of steroid derivative and then
treated with [3H]thymidine as described above. IC50 values were
calculated with SigmaPlot-11.0.
Progesterone receptor assay
The relative binding affinities of steroid modulators to PR were
measured by a binding assay on a pool of breast tumour cytosols
using [3H]ORG-2058 (Organon) as tracer19 (Experimental Section
in SI).
Activation of human pregnane X receptor by steroid derivatives
The activation of hPXR was evaluated using a luminescent
assay20,21 (Experimental Section in SI).
Flow cytometry
HL60-MRP1 and MCF7-MTX cells (106 cells) were incubated for
1 h at 37 C in 1ml of their respective culture medium containing
105M of either daunorubicin for HL60-MRP1 cells or mitoxan-
trone for MCF7-MTX cells, in the presence or absence of steroid
modulators (10mM)22.
Animals
Female CB17-SCID (severe combined immunodeficient) mice
(Charles River) were bred under pathogen-free conditions at the
animal facility of our University. Animals were treated in accord-
ance with the European Union and French laws for laboratory ani-
mal care after approval by the local animal ethical committee. The
animals were kept in conventional housing. Access to food and
water was unrestricted. All mice were 5/6weeks-old at the time of
tumour implantation.
Xenografts of tumour cells and treatments of mice
K562 sensitive cells and K562/R7 or NCI-H295R resistant cells
[3 106 cells in 200 mL of a 50/50 mixture of PBS and Matrigel
(Beckton-Dickinson)] were subcutaneously injected in both flanks
of mice on day 1. Mice were then divided into four groups of 5 or
6 animals: group I received vehicle alone (100 mL/mouse of physio-
logical serum containing 6% of benzyl alcohol); group II received
simultaneously doxorubicin (1.5mg/kg/mouse, dissolved in 50 mL
of physiological serum) and vehicle (100 mL); group III received the
steroid modulator 4 alone (8mg/kg/mouse, dissolved in 100 mL of
vehicle); group IV received simultaneously doxorubicin (1.5mg/kg/
mouse, dissolved in 50mL of physiological serum) and the steroid
modulator 4 (8mg/kg/mouse, dissolved in 100 mL of vehicle) or
cyclosporin A (10mg/kg, dissolved in 100 mL of vehicle). This regi-
men corresponds to maximal doses for doxorubicin and modula-
tor. For mice injected with NCI-H295R cells which developed a
solid tumour 20 days later, treatments started on day 2 after cell
injection. For K562/R7 cells which developed a solid tumour
40 days after injection of cells, treatment started on day 20 after
injection. All treatments were ip administered every 4 days for
1month. During treatment, mice were weighed and tumour pro-
gression was followed twice a week with an electronic caliper,
using the formula: tumour volume (mm3)¼length (mm)width2/2.
Animals were euthanized when tumour volume exceeded
3500mm3 to avoid animal discomfort or if conditions suggested
excessive suffering. Results were expressed as mean± SE of
tumour volumes in each group.
Pharmacokinetic studies
Plasmatic concentrations of doxorubicin were determined after ip
injections of doxorubicin (10mg/kg dissolved in 50mL of physio-
logical serum) alone or in the presence of steroid modulator 4
(20mg/kg, dissolved in 200 mL of vehicle) to three female OF1
mice per time point (0.5, 1, 2, 4, 8 and 24 h) (Experimental Section
in SI).
Statistical analyses
Data were expressed as means ± SE from a minimum of three
independent experiments and were analysed by ANOVA followed
by Student’s t-test. A p value <.05 was considered statistically
significant.
Results
mRNA expression of ABC transporters in resistant NCI-H295R
and K562/R7 tumour cell lines
RT-qPCR experiments made on NCI-H295R cells showed that P-gp/
MDR1 mRNA was the major product (1525 copies, normalised by
G3PDH) whereas very low amounts of mRNAs were expressed for
the other ABC transporters MRP1 (ABCC1) (0.6 copy/G3PDH), BCRP
(ABCG2) (0.2 copy/G3PDH) and MRP2 (ABCC2) (0.02 copy/G3PDH).
These levels are much lower than reported for K562/R7 cells15 but
remain in similar ratios. The presence of P-gp in the two NCI-
H295R and K562/R7 cell lines was confirmed by Western blot
using C219 anti-P-gp antibody (data not shown).
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Measurements of the cytotoxicity of doxorubicin in K562/R7
cells in the presence of steroid modulators using a
[3H]thymidine assay
Cytotoxicity of doxorubicin in NCI-H295R and K562/R7 cells was
measured by a [3H]thymidine incorporation assay less prone to
steroid interferences than the MTT assay previously employed for
non-steroidogenic K562/R7 cells15, owing to the risk of steroid
interactions with the mitochondrial succinate dehydrogenase
involved in MTT reduction20. In a preliminary experiment, K562/R7
cells were treated with doxorubicin alone and in the presence of
progesterone or cyclosporin A (1 mM) as reference modulators of
P-gp. Measurements with MTT or [3H]thymidine assays led to com-
parable IC50 values for doxorubicin. Similar measurements with
the [3H]thymidine assay were made using a panel of four selected
disubstituted 5a/b-pregnane modulators 3, 4, 6, and 9 (Figure
1)15. The results (Table S1) showed that the 7a-OBz,11a(R)-OTHP-
5b-pregnanedione lead compound 4 remained the most active
modulator as found previously using the MTT assay15. However,
many differences could be observed for the other steroid analogs
owing possibly in part to the greater sensitivity of the thymidine
assay. The intrinsic cytotoxicity of the four tested steroid modula-
tors was estimated by treatment of nonresistant K562 cells for
24 h with a high steroid concentration (10mM). The results (Table
S1) showed that compounds 4 and 9 were less toxic than cyclo-
sporin A as found previously using the MTT assay15.
Resistance of NCI-H295R and K562/R7 cells to different classes
of cytotoxic drugs
Different cytotoxic drugs (vinblastine, paclitaxel, mitoxantrone, col-
chicine, vinorelbine) were also tested on the two NCI-H295R and
K562/R7 cell lines in comparison with doxorubicin (Table S2).
Measurements by the [3H]thymidine assay after treatment for 24 h
with varying concentrations of these drugs (0.01–100 mM) showed
a strong resistance of NCI-H295R cells to doxorubicin reaching an
IC50 value approximately one-half of that found for K562/R7 cells
despite a much lower level of P-gp. The NCI-H295R cells also
revealed a strong resistance to mitoxantrone (IC50 value 2-fold
that of K562/R7 cells) but a low resistance to vinorelbine or pacli-
taxel and a very low resistance to vinblastine and colchicine. In
contrast, K562/R7 cells, very resistant to doxorubicin, were found
moderately resistant to mitoxantrone colchicine and vinblastine,
but less resistant to vinorelbine and paclitaxel.
Modulation of resistance to doxorubicin by different synthetic
steroid derivatives in NCI-H295R and K562/R7cells
This study was undertaken to evaluate the modulating effects of
nine steroid modulators 1–9 (Figure 1) selected from our previous
in vitro study on K562/R7 cells15. Measurements were made on
both NCI-H295R and K562/R7 cells, incubated for 24 h with doxo-
rubicin (1 mM) in the absence or presence of steroid modulator
(0.1, 1, and 10 mM). The results (Table 1) are expressed as the per-
centage of [3H]thymidine incorporated in treated cells vs.
untreated cells. Treatment with doxorubicin alone led to a lower
incorporation of [3H]thymidine in NCI-H295R cells (60%) than in
K562/R7 cells (80%). In the presence of steroid modulators, the
decrease in [3H]thymidine incorporation was roughly proportional
to the steroid concentration. The efficiencies of the tested steroid
derivatives were most often similar in the two cell lines, with
exceptions for the dibenzoate 6 and the di-OTHP ethers 3 and 7,
both less active in NCI-H295R cells, owing possibly to partial meta-
bolic conversion. In both cell lines, 7a-OBz,11a(R)-OTHP-5b-preg-
nane-3,20-dione 4 was the most efficient modulator in contrast to
its 11a(S)-OTHP diastereoisomer 5 having a much lower efficiency.
However, the efficiency of the steroid modulator 4 for NCI-H295R
cells became lower than that of cyclosporin A, in contrast to the
order observed for K562/R7 cells.
Evaluation of interactions of pregnane modulators with human
progesterone and pregnane X receptors
In order to evaluate the risks of unwanted side-effects, the four
more potent 5a/b-pregnane modulators 3, 4, 6, and 9 were tested
for their ability to activate PR as well as hPXR owing to its role in
the expression of ABC transporters and drug-metabolising
enzymes21. None of the steroids at concentrations up to their
respective IC50 values was able to significantly compete with the
reference PR ligand [3H]ORG2058 (Figure S1(A)). Measurements of
the activation of hPXR by a luminescent assay23 revealed different
but significant effects of the four steroids. Activation increased
between 0.1 and 1 mM concentrations of modulators (Figure
S1(B)), but never reached the level induced by the reference non-
steroidal hPXR activator SR12813. The lowest effect was observed
for the steroid modulator 4 up to a 5 mM concentration.
Table 1. Modulation of resistance to doxorubicin by pregnane steroid derivatives.
Modulators (10 mM)
% [3H]thymidine incorporation (co-treated/
untreated cells)a
Structure H295R cells K562/R7 cells
pregn-4-ene-3,20-dione derivatives
progesterone 17a-H 31.3±3.8 37.5±2.5
1 17a(Rþ S)-OTHP 11.6±1.9 13.1±0.7
5b-pregnane-3,20-dione derivatives
2 11a(S)-OTHP 25.0±1.6 19.3±0.2
3 11a(S),17a(R)-diOTHP 12.6±2.8 2.7±0.7
4 7a-OBz,11a(R)-OTHP 3.6±0.9 1.4±0.4
5 7a-OBz,11a(S)-OTHP 13.4±3.1 13.3±3.8
6 7a,11a-diOBz 14.8±0.8 5.7±0.3
5a-pregnane-3,20-dione derivatives
7 7a-OBz,11a(R)-OTHP 19.0±2.2 2.2±0.8
8 7a-OBz,11a(S)-OTHP 13.5±1.3 16.0±2.3
9 7a,11a-diOBz 9.5±2.7 6.1±2
cyclosporin A (non-steroidal modulator) 1.6±0.5 2.2±0.3
aCells were treated with doxorubicin (10 lM) in the presence of steroid or cyclosporin A modulators (10lM) for 24 h. Efficiency of modula-
tors was evaluated through the strength of the decreasing effect on the percentage of [3H]thymidine incorporation in surviving co-
treated cells vs. untreated cells. Significance was determined by ANOVA test, p< .05 vs. progesterone, p< .001 vs. progesterone.
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Specificity of the interaction of steroids with P-gp vs. other ABC
transporters
The potency of the four steroid modulators 3, 4, 6, or 9 to interact
with MRP1 or BCRP was evaluated by measuring their modulating
effects on the accumulation of daunorubicin in HL60-MRP1 cells
or of mitoxantrone in MCF7-MTX cells (expressing BCRP), using
flow cytometry. In HL60-MRP1 cells, the presence of 10mM of ster-
oid modulators led to a 1.3–1.7-fold increase of daunorubicin
accumulation lower than the 2.5–2.9-fold increase found for P-gp-
expressing K562/R7 cells15 (Table 2). In MCF7-MTX cells, the effects
on mitoxantrone accumulation produced by the same steroids
were much lower (2-fold increase) than that produced by elacri-
dar, a reference modulator of BCRP (11-fold increase). Therefore,
the four tested steroid modulators appeared to maintain a signifi-
cant degree of specificity for P-gp in MDR inhibition assays in
vitro. Interactions with MRP2, present only in trace amounts in
K562/R7 or NCI-H295R cells, were not evaluated.
In vivo efficiency of steroid modulator 4 in xenografted
mice models
The in vivo activity of the steroid modulator 4 on MDR reversion
was evaluated by monitoring tumour development in CB17-SCID
mice xenografted with either NCI-H295R or K562/R7 cells. In pre-
liminary experiments, the maximum tolerated dose of doxorubicin
was evaluated to 1.5mg/kg, whereas the dose of the steroid
modulator 4 was limited to 8mg/kg by its solubility.
For NCI-H295R cells, implantation of tumours in mice after sc
injection was rapid (20 days) and treatments began 1day after this
injection. For K562/R7 cells, development of tumours in mice after
sc injection was much slower (40 days) and therefore, treatments
began 20 days after this injection.
In mice xenografted with K562/R7 cells, treatments with vehicle
alone (group I), doxorubicin alone (group II) or steroid modulator
4 alone (group III) remained inefficient. The tumour volume
reached either 500mm3 (group I) or 200mm3 (groups II and III)
after the last injection (32 days) and then rapidly increased up to
ca. 2600–3000mm3 after 8–18 additional days without treatment
(Figure 2(A1)). By contrast, co-treatment with doxorubicin and the
steroid modulator 4 (group IV) prevented tumour development
up to the last injection (32 days), then significantly limited tumour
growth leading to a volume plateauing at ca. 1200mm3, even
after 38 further days without treatment. No apparent toxic effects
were detected (no mouse died or presented any sign of morbid-
ity). For mice xenografted with NCI-H295R cells, results (Figure
2(A2)) were similar to those observed for mice xenografted with
K562/R7. Treatments with vehicle alone, doxorubicin, or steroid
modulator 4 alone were inefficient, all leading to a tumour vol-
ume increasing up to ca. 1100mm3 after 45 days including 13 days
without treatment. In contrast, co-treatment with doxorubicin and
the steroid modulator 4 reduced tumour development plateauing
to 440mm3 after 40 days including 8 days without treatment. No
further increase of tumour volume occurred up to 25 additional
days without treatment after which animals were sacrificed. No
loss of weight or signs of morbidity were observed.
Conversely, co-administration of doxorubicin with the cyclo-
sporin A modulator was found to be toxic (only 2 of 6 mice sur-
vived after the 4th injection – 16 days of treatment). This
treatment was stopped to preserve the surviving mice for which
the tumour volume (1500mm3 after additional 49 days without
treatment) was lower than in groups of untreated mice. On the
other hand, treatment with cyclosporin A alone led to a tumour
volume lower than in untreated mice (Figure 2(B)) suggesting an
intrinsic toxicity of cyclosporin A.
For mice xenografted with sensitive K562 cells, treatment for
30 days with doxorubicin alone stabilised the tumour volume at
ca. 2000mm3, representing also nearly one-half of that reached
without treatment (Figure S2).
Effect of steroid modulator 4 on pharmacokinetics of
doxorubicin
Several P-gp modulators have been reported to alter the pharma-
cokinetic properties of cytotoxic drugs18. The time course of
plasma concentration of doxorubicin was measured in OF1 mice
receiving a single ip dose of doxorubicin (4mg/kg) in the absence
and in the presence of steroid modulator 4 (20mg/kg) at concen-
trations much higher than those tolerable by SCID mice. The
results (Figure S3) showed no modifications of plasma concentra-
tions of doxorubicin when co-administered with modulator 4, indi-
cating an absence of effect on the plasmatic half-life of
doxorubicin.
Discussion and conclusions
This work reports in vitro and in vivo data on K562/R7 and NCI-
H295R cell lines that revealed the potency of the 7a-OBz,11a(R)-
OTHP-5b-pregnane-3,20-dione lead compound 415 to modulate P-
gp-mediated MDR and to inhibit the development of tumour cell
xenografts. The K562/R7 cells, highly resistant to doxorubicin were
found to express a much higher level of P-gp than the intrinsically
resistant NCI-H295R cells that showed nevertheless half the resist-
ance (IC50) to doxorubicin of that of K562/R7 cells (Table S1). This
may suggest the presence of other non-elucidated factors than
inhibition of P-gp efflux.
Comparisons of the modulating effects of steroid derivatives
on doxorubicin resistance for the two NCI-H295R and K562/R7 cell
lines as measured in this study either by the [3H]thymidine assay
insensitive to potential steroid interferences in steroidogenic NCI-
H295R cells or by the usual MTT assay15 revealed partially similar
profiles. In all cases, the steroid modulator 4 showed the strongest
modulating activity but the activities of compounds 3 and 7 were
much lower for NCI-H295R cells (Table 1). None of the tested
Table 2. Specificity of the interaction of steroids 3,4,6,9 with other ABC transporters.
Modulators (10 mM) K562/R7 cells (P-gp)a HL60-MRP1 cells (MRP1)a MCF7-MTX cells (BCRP)b
3 2.5 ± 0.08 1.40 ± 0.10 1.80 ± 0.10
4 2.9 ± 0.15 1.35 ± 0.09 1.85 ± 0.09
6 2.6 ± 0.20 1.35 ± 0.12 1.70 ± 0.10
9 2.5 ± 0.10 1.70 ± 0.20 1.50 ± 0.15
aCells were treated with 10 mM of daunorubicin (K562/R7 and HL60-MRP1 cells) in the presence or absence
of 10 mM of steroid modulators and analysed by flow cytometry.
bCells were treated with 10 lM of mitoxantrone in presence or absence of 10mM of steroid modulators
and analysed by flow cytometry. All the results are expressed as fluorescence ratio with/without
modulator.
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steroid modulators was found more active in NCI-H295R cells than
in K562/R7 cells. The strongest activity of the steroid modulator 4
observed for both cell lines points to the conclusion that this ster-
oid modulator is particularly resistant to metabolism in steroido-
genic NCI-H295R cells that may provide a useful model for
evaluating the risks of steroid metabolism in vivo. However, the
stronger efficiency of steroid modulator 4 vs. cyclosporin A
observed for K562/R7 cells was not maintained for H295R cells.
Neither the most efficient modulator 4 nor the three other less
active steroids 3, 6, and 9 revealed any significant binding affinity
for the progesterone receptor of human breast tumours. However,
these four steroids were all found able to activate the hPXR of
HG5N-PXR cells at the concentration of 0.4 mM (employed to
reverse resistance to doxorubicin), among which compound 4
revealed the lowest effect. Activation of hPXR is known to increase
chemoresistance via mechanisms involving overexpression of
transport proteins and drug-metabolising enzymes24 and might
become a major unwanted side-effect in the case of tumour cells
expressing PXR, although beneficial effects have also been
reported25. None of the tested derivatives could strongly reverse
the resistance mediated by the two other ABC transport proteins
MRP1 or BCRP, measured in HL60-MRP1 cells and in MCF7-MTX
cells, respectively and present only in low amounts in the two
studied K562/R7 or NCI-H295R cell lines.
Taken together, all these results point to the conclusion that
compound 4, the only potent steroid modulator found for NCI-
H295R cells, was the most suitable candidate for undertaking in
vivo assays.
In vivo experiments were performed on xenografts of K562/R7
or NCI-H295R cells introduced on SCID mice26. The maximum tol-
erated dose of doxorubicin (1.5mg/kg) was limited by the
extreme sensitivity of SCID mice to doxorubicin toxicity, owing to
their deficit in cellular mechanisms of DNA repair27. The maximum
dose of the 5b-pregnane modulator 4 (8mg/kg) was imposed by
its limit of solubility optimised by employing the lowest amount
of benzyl alcohol (6%) able to maintain the steroid soluble in
physiological serum without impairing mice survival. Non-xeno-
grafted SCID mice co-treated with these optimised doses of doxo-
rubicin and steroid modulator could survive beyond 40 days, thus
suggesting the absence of strong toxic side-effects of
this treatment.
The potency of the steroid modulator 4 to inhibit tumour
development in vivo was demonstrated in mice xenografted with
either K562/R7 or NCI-H295R cells. In both cases, co-treatment
with doxorubicin and modulator 4, limited to 32 days in this study,
reduced the tumour volume from 30–50% of that observed after
treatments with only doxorubicin, steroid modulator or vehicle
alone. These controls showed very weak effects on tumour devel-
opment, thus confirming that xenografted cells remained highly
resistant and suggesting the absence of intrinsic toxicity of the
steroid. The co-treatment also increased the survival time up to
65–70 days without death cases. In contrast, control mice treated
only either with doxorubicin or modulator 4 had to be sacrificed
at 45–50 days, according to ethical rules, owing to excessive
tumour size and poor health status. A complementary test made
on mice xenografted with K562/R7 cells co-treated with doxorubi-
cin and cyclosporin A showed a higher toxicity for mice and a
lesser efficiency on tumour development as compared with co-
treatment using the steroid modulator 4. However, co-administra-
tion of doxorubicin and modulator 4 remained unable to block
totally tumour development, owing possibly to the limited dose
of doxorubicin that could be safely employed for treatments on
SCID mice. This partial efficiency is in keeping with the results of
parallel experiments made on SCID mice xenografted with sensi-
tive K562 cells treated with doxorubicin alone.
On the other hand, compound 4 did not influence plasma
pharmacokinetics of doxorubicin (tested on OF1 mice) thus sup-
porting the assumption that the reversion of resistance is not
caused by an increase of the plasma concentration of doxorubicin,
but is more probably related to an inhibition of P-gp activity.
Figure 2. In vivo effect of co-treatment with doxorubicinþ steroid modulator 4
or cyclosporin A on tumour volume of K562/R7 cell xenografts (panel A1) and
H295R cell xenografts (panel A2). In vivo effect of co-treatment with doxorubi-
cinþ cyclosporine A on tumour volume of K562/R7 cell xenografts (panel B).
Vehicle, doxorubicin, modulator 4 and doxorubicinþmodulator 4 or cyclosporin
A were administered ip. every 4 days during one month to groups of 6 mice as
described in SI (Experimental Section). Results are expressed as mean± SE.
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It should be noted that the choice of doxorubicin as cytotoxic
agent in these comparative in vitro and in vivo evaluations of ster-
oid modulators was made in the view to rely on a well-known
drug despite its strong cardiotoxicity and its possible PXR-medi-
ated stimulating effect on MDR1 expression28.
The results of this study are in agreement with similar in vitro
and in vivo evaluations made on the human osteosarcoma MG63/
DOX cell line overexpressing P-gp after co-treatment with doxo-
rubicin and nilotinib29. The efficiency of the steroid modulator 4
supports the concept that potent MDR modulators can be
obtained by simple esterification and/or etherification of hydroxy-
lated steroid precursors. It remains to determine whether struc-
tural refinements of the substituents of steroid modulator 4 could
reduce activation of hPXR and/or increase biodisponibility to fur-
ther improve in vivo efficiency.
Acknowledgements
The authors and especially Ghina Alameh are indebted to Drs. G.
Dayan and A. di Pietro for fruitful discussions and help for bio-
logical studies, including the gifts of HL60-MRP1 and MCF7-MTX
cell lines. The authors also thank Dr. F. Descotes for her help in
interaction studies with PR.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This study was supported by funds from INSERM, “Universite
Claude Bernard Lyon 1” and “Hospices Civils de Lyon.”
ORCID
Marc Rolland de Ravel http://orcid.org/0000-0002-1642-9667
Elisabeth Mappus http://orcid.org/0000-0003-0203-2746
Luc Rocheblave http://orcid.org/0000-0002-3300-0416
Thierry Lomberget http://orcid.org/0000-0002-4071-0002
Charles Dumontet http://orcid.org/0000-0003-1875-134X
Marc Le Borgne http://orcid.org/0000-0003-1398-075X
Catherine Grenot http://orcid.org/0000-0002-7011-9002
Claude Y. Cuilleron http://orcid.org/0000-0001-8572-6334
References
1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in
cancer: role of ATP-dependent transporters. Nat Rev Cancer
2002;2:48–58.
2. Teodori E, Dei S, Scapecchi S, et al. The medicinal chemistry
of multidrug resistance (MDR) reversing drugs. Il Farmaco
2002;57:385–415.
3. Zhao XQ, Xie JD, Chen XG, et al. Neratinib reverses ATP-
binding cassette B1-mediated chemotherapeutic drug resist-
ance in vitro, in vivo, and ex vivo. Mol Pharmacol 2012;82:
47–58.
4. Teodori E, Dei S, Scapecchi S, et al. The functions and struc-
tures of ABC transporters: implications for the design of
new inhibitors of Pgp and MRP1 to control multidrug resist-
ance (MDR). Curr Drug Targets 2006;7:893–999.
5. Robert J, Jarry C. Multidrug resistance reversal agents. J Med
Chem 2003;46:4805–17.
6. Orlowski S, Mir LM, Belehradek J, et al. Effects of steroids
and verapamil on P-glycoprotein ATPase activity: progester-
one, desoxycorticosterone, corticosterone and verapamil are
mutually non-exclusive modulators. Biochem J 1996;317:
515–22.
7. Peer M, Csaszar E, Vorlaufer E, et al. Photoaffinity labeling of
P-glycoprotein. Mini Rev Med Chem 2005;5:165–72.
8. Loo TW, Bartlett MC, Clarke DM. The drug-binding pocket
of the human multidrug resistance P-glycoprotein is
accessible to the aqueous medium. Biochemistry 2004;43:
12081–9.
9. Robert J. Approaches to multidrug resistance reversal.
Expert Opin Investig Drugs 1998;7:929–39.
10. Yang CP, DePinho SG, Greenberger LM, et al. Progesterone
interacts with P-glycoprotein in multidrug-resistant cells and
in the endometrium of gravid uterus. J Biol Chem 1989;264:
782–8.
11. Barnes KM, Dickstein B, Cutler Jr GB, et al. Steroid treatment,
accumulation, and antagonism of P-glycoprotein in multi-
drug-resistant cells. Biochemistry 1996;35:4820–7.
12. Gruol DJ, Zee MC, Trotter J, et al. Reversal of multidrug
resistance by RU 486. Cancer Res 1994;54:3088–91.
13. Leonessa F, Kim JH, Ghiorghis A, et al. C-7 Analogues of pro-
gesterone as potent inhibitors of the P-glycoprotein efflux
pump. J Med Chem 2002;45:390–8.
14. Perez-Victoria FJ, Conseil G, Munoz-Martinez F, et al.
RU49953: a non-hormonal steroid derivative that potently
inhibits P-glycoprotein and reverts cellular multidrug resist-
ance. Cell Mol Life Sci 2003;60:526–35.
15. Rolland de Ravel M, Alameh G, Melikian M, et al. Synthesis
of new steroidal inhibitors of P-glycoprotein-mediated multi-
drug resistance and biological evaluation on K562/R7
erythroleukemia cells. J Med Chem 2015;58:1832–45.
16. Gazdar AF, Oie HK, Shackleton CH, et al. Establishment and
characterization of a human adrenocortical carcinoma cell
line that expresses multiple pathways of steroid biosyn-
thesis. Cancer Res 1990;50:5488–96.
17. Boumendjel A, Boccard J, Carrupt PA, et al. Antimitotic and
antiproliferative activities of chalcones: forward structure-
activity relationship. J Med Chem 2008;51:2307–10.
18. Sparreboom A, Nooter K. Does P-glycoprotein play a role in
anticancer drug pharmacokinetics. Drug Resist Updat 2000;3:
357–63.
19. Descotes F, Ville G, Bobin JY, et al. Tissue extraction proce-
dures for investigation of urokinase plasminogen activator
(uPA) and its inhibitors PAI-1 and PAI-2 in human breast car-
cinomas. Breast Cancer Res Treat 1998;49:135–43.
20. Joly-Pharaboz MO, Ruffion A, Roch A, et al. Inhibition of
growth and induction of apoptosis by androgens of a vari-
ant of LNCaP cell line. J Steroid Biochem Mol Biol 2000;73:
237–49.
21. Shukla SJ, Sakamuru S, Huang R, et al. Identification of clin-
ically used drugs that activate pregnane X receptors. Drug
Metab Dispos 2011;39:151–9.
22. Raad I, Terreux R, Richomme P, et al. Structure-activity rela-
tionship of natural and synthetic coumarins inhibiting the
multidrug transporter P-glycoprotein. Bioorg Med Chem
2006;14:6979–87.
23. Lemaire G, Mnif W, Pascussi JM, et al. Identification of new
human pregnane X receptor ligands among pesticides
690 G. ALAMEH ET AL.
using a stable reporter cell system. Toxicol Sci 2006;91:
501–9.
24. Pondugula SR, Pavek P, Mani S. Pregnane X receptor and
cancer: context-specificity is key. Nucl Receptor Res 2016;3:
101198.
25. Qiao E, Ji M, Wu J, et al. Expression of the PXR gene in vari-
ous types of cancer and drug resistance. Oncol Lett 2013;5:
1093–100.
26. Bellamy WT, Odeleye A, Finley P, et al. An in vivo model of
human multidrug-resistant multiple myeloma in SCID mice.
Am J Pathol 1993;142:691–7.
27. Williams SS, Alosco TR, Mayhew E, et al. Arrest of human
lung tumor xenograft growth in severe combined immuno-
deficient mice using doxorubicin encapsulated in sterically
stabilized liposomes. Cancer Res 1993;53:3964–7.
28. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyop-
athy from the cardiotoxic mechanisms to management.
Prog Cardiovasc Dis 2007;49:330–52.
29. Zhou ZY, Wan LL, Yang QJ, et al. Nilotinib reverses ABCB1/P-
glycoprotein-mediated multidrug resistance but increases
cardiotoxicity of doxorubicin in a MDR xenograft model.
Toxicol Lett 2016;259:124–32.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 691
